Potheni and colleagues mention:
Even with the best basic suggested treatment, some will have persistent infections. The debate is between these being living cysts, persisters, and biofilm forms. While others say this is non-living effects of particles or inflammatory changes or many other reasons. I think both are true.
And we should note Lyme is a profoundly slow growing organism, and my appeal is that means we are dealing with a slow growing infection a little like TB, and noty rapidly reproducing Strep.
1. Lyme disease is “one of most common vector-borne diseases, reporting more than 300,000 cases annually in the United States. ” [The 300 world borrelia are not tested, only one. The super common TBRF are ignored, and Lyme has 22-27 evasion techniques as mentioned in our Healthcare Workers Babesia foundational book in 2006].
2. After basic treatment of doxycycline “some have prolonged symptoms of fatigue, musculoskeletal pain, and perceived cognitive impairment.” These “may persist over six months.”
3. They feel “growing evidence from recent studies suggests it might be due to the existence of drug-tolerant persisters.” [Bold JS]
4. In the lab azlocillin and cefotaxime effects on Lyme bacteria were compared to the typical initial treatment of doxycycline.
5. They “found that azlocillin completely kills [both] late log phase [fast growing] and 7–10 days old stationary phase B. burgdorferi.
6. “Our results also demonstrate that azlocillin and cefotaxime can effectively kill in vitro [lab] doxycycline-tolerant B. burgdorferi.”
7. ” Furthermore, when tested in vivo [in a living mouse], azlocillin has shown good efficacy against B. burgdorferi in mice model.
8. “These seminal findings strongly suggest that azlocillin can be effective in treating B. burgdorferi sensu stricto JLB31 infection and furthermore in depth research is necessary to evaluate its potential use for Lyme disease therapy.
More to come….